8-K
filed June 5, 2026, 8:10 AM ET
ticker PMVP
CIK 0001699382
other material
confidence high
sentiment neutral
materiality 0.15
PMV Pharma annual meeting reelects Mack and Stelzer as Class III directors
PMV Pharmaceuticals, Inc.
- David H. Mack, Ph.D. elected with 15,693,907 for, 6,248,461 withheld; Laurie Stelzer with 11,261,111 for, 10,681,257 withheld.
- Non-binding say-on-pay resolution approved: 15,015,578 for, 6,468,718 against, 458,072 abstain.
- Ernst & Young ratified as independent auditor for FY2026: 28,379,108 for, 536,302 against, 2,370 abstain.
- Broker non-votes on director election and say-on-pay totaled 6,975,412 shares.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
PMV Pharmaceuticals, Inc. shareholders approved Non-Binding Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers at the 2026-06-04 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-04
Exact text from the filing
The Company’s stockholders approved, on a non-binding advisory basis, the compensation paid to its named executive officers as described in the Company’s definitive proxy statement on Schedule 14A, filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 22, 2026 (the “Proxy Statement”).
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
PMV Pharmaceuticals, Inc. shareholders approved Election of Directors at the 2026-06-04 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-04
Exact text from the filing
The Company’s stockholders elected the two persons listed below as Class III Directors, each to serve until the Company’s 2029 annual meeting of stockholders and until their respective successors has been duly elected and qualified, or until the earlier of the respective director’s death, resignation or removal.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
PMV Pharmaceuticals, Inc. shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2026-06-04 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-04
Exact text from the filing
The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.